13D Filing: Ventech Capital II and Eyegate Pharmaceuticals Inc (EYEG)

Page 10 of 11

Page 10 of 11 – SEC Filing

CUSIP No. 30233M 107 13D Page 10 of 11

(iii)      sole power to dispose or to direct the disposition:
See line 9 of the cover sheets.

(iv)      shared power to dispose or to direct the disposition:
See line 10 of the cover sheets.

(c) None of the Reporting Persons has effected any transaction
in the Common Stock during the last 60 days.
(d) No other person is known to have the right to receive or the
power to direct the receipt of dividends from, or any proceeds from the sale of, Shares
beneficially owned by any of the Reporting Persons.
(e) Not applicable.

As a result primarily of offerings of Common Stock by the Issuer
in August 2015, June 2016 and June 2017, the Reporting Persons’ ownership in the Issuer as reported on the original Schedule
13D has been diluted.

Item 7.    Material to be Filed as Exhibits.

Exhibit 1 — Agreement regarding filing of joint Schedule
13D.

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)

Page 10 of 11